ClinicalTrials.gg
CompletedNCT00814073AB06006Updated Dec 3, 2019

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

A Phase 3 interventional study of Masitinib and Placebo in Indolent Systemic Mastocytosis, sponsored by AB Science. Completed at 24 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-12-03.

Sponsored by AB Science · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2015, 11 years ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Dec 2018.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies in Mastocytosis, Systemic with a site in France — 6 open to participants now, 8 under way, 2 of them phase 3. Mastocytosis, Systemic · France.

Enrollment
8th of 15
135 · median 135
Started
2008
with 1 other
Phase 3
3 of 18
1 open now
Registered
4th of 18
by date
Lead sponsor
2 of 18
AB Science

Among the 18 studies in Mastocytosis, Systemic with a site in France, this one is the 8th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2008, is one of 3 in phase 3, and was the 4th registered.

Mastocytosis, Systemic

56 studies on the registry are indexed under Mastocytosis, Systemic; 16 are open to participants now.

Browse Mastocytosis, Systemic studies →

Open to participants now

6 of the 18 studies in Mastocytosis, Systemic with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 14 Mastocytosis, Systemic studies recruiting now, 12 (86%) set no upper age limit and 2 (14%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Mastocytosis, Systemic with a site in France, or all of them as a file.
02

Study summary

The objective of this study is to compare the safety and efficacy of masitinib (AB1010) to placebo in patients with mastocytosis with handicap.

Read the detailed description

This was a prospective, multicenter, randomized, placebo-controlled, parallel-group, phase 3 study, conducted in 15 countries, evaluating the efficacy and safety of masitinib (6 mg/kg/day administered orally in two daily intakes over 24-weeks with a double-blind extension period possible) for the treatment of indolent systemic mastocytosis, smoldering mastocytosis or cutaneous mastocytosis, in patients with mast cells mediator release symptoms that are refractory to conventional symptomatic treatment.

A study protocol amendment restricted enrolment to patients with severe indolent and smoldering systemic mastocytosis. The objective of this phase 3 study was therefore to evaluate masitinib efficacy and safety in severe systemic mastocytosis patients, with or without D816V mutation of c-Kit. The primary objective of the phase 3 study was to detect a statistically significant difference between masitinib (plus optimal concomitant symptomatic treatments) and placebo (plus optimal concomitant symptomatic treatments) in cumulative response on four severe symptoms, referred to also as handicaps.

03

Conditions studied

  • Indolent Systemic Mastocytosis

Keywords

  • Mastocytosis with handicap
  • Mastocytosis
  • Mast cell
  • Mast cell infiltration
  • Skin
  • Bone marrow
  • Pruritus
  • Flushes
  • c-kit
  • c-kit mutation
  • Wild Type
  • Mutation Asp-816-Val(D816V)
  • Indolent systemic mastocytosis
  • smoldering systemic mastocytosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient with one of the following documented mastocytosis as per WHO classification: Smouldering Systemic Mastocytosis, Severe Indolent Mastocytosis
  2. Patient with documented mastocytosis and evaluable disease based upon histological criteria: typical infiltrates of mast cells in a multifocal or diffuse pattern in skin and/or bone marrow
  3. Patient with documented treatment failure of his/her handicap(s) with at least one of the following therapy used at optimized dose: Anti H1, Anti H2, Proton pump inhibitor, Osteoclast inhibitor, Cromoglycate Sodium, Antileukotriene
  4. Handicapped status defined as at least two of the following handicaps, including at least one among pruritus, flushes, depression and fatigue: pruritus score ≥ 9, number of flushes per week ≥ 8, Hamilton rating scale for depression (HAMD-17) score ≥ 19, number of stools per day ≥ 4, number of mictions per day ≥ 8, Fatigue Impact Scale total score (asthenia) ≥ 75
  5. Patients with OPA ≥ 2 (moderate to intolerable general handicap)
  6. ≤ 2
  7. Patient with adequate organ function

Exclusion criteria

Exclusion Criteria:

  1. Patient with one of the following mastocytosis: Cutaneous Mastocytosis, Not documented Smouldering Systemic Mastocytosis or Indolent Systemic Mastocytosis, Systemic Mastocytosis with an Associated clonal Hematologic Non Mast cell lineage Disease (SM-AHNMD), Mast cell leukemia (MCL), Aggressive systemic mastocytosis (ASM)
  2. Previous treatment with any Tyrosine Kinase Inhibitor
  3. Patient with recent cardiac history of: Acute coronary syndrome, Acute heart failure, Significant ventricular arrhythmia; patient with cardiac failure class III or IV; Syncope without known aetiology within 3 months, uncontrolled severe hypertension.
  4. Patient with any condition that the physician judges could be detrimental to subjects participating in this study; including any deviations from normal clinical laboratory values or concurrent medical events Previous treatment
  5. Change in the symptomatic treatment of mastocytosis or administration of any new treatment of mastocytosis within 4 weeks prior to baseline
  6. Treatment with any agent within 4 weeks prior to baseline
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Masitinib & BSC

    Masitinib (6 mg/kg/day) administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)

    Drug: Masitinib · Other: Best Supportive Care

  • Placebo comparator
    Placebo & BSC

    Matching placebo administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)

    Drug: Placebo · Other: Best Supportive Care

Interventions

  • Masitinib 6 mg/kg/day

    Also known as: AB1010

  • DrugPlacebo

    Matching placebo

  • OtherBest Supportive Care

    Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglicate, antidepressants, leukotriene antagonists, interferon-alpha, 2-CdA, and corticosteroids.

06

What researchers measure

Primary outcomes

  1. Cumulative response (4R75%)

    The prospectively declared primary endpoint (4R75%) was cumulative response in at least one of four severe baseline symptoms of mast cell mediator release (pruritus, flushes, depression, or asthenia). Response was defined as a 75% improvement from baseline for any of these four symptoms. Cumulative response was defined as the number of actual responses between weeks 8 and 24, divided by the total number of possible responses over the same treatment period (ie, with five scheduled visits, each patient had a maximum of five to 20 possible responses depending on the number of severe baseline symptoms).

    Time frame: 24 weeks

Secondary outcomes

  1. Cumulative response (3R75%)

    Cumulative response in at least one of three severe baseline symptoms (pruritus, flushes, or depression)

    Time frame: 24 weeks

  2. Cumulative response (2R75%)

    Cumulative response in at least one of three severe baseline symptoms (pruritus or flushes)

    Time frame: 24 weeks

07

Study locations

24 sites
  • UC Davis Health System , Department of Dermatology
    Sacramento, California 95816, United States
  • MD Anderson Cancer Centre
    Houston, Texas 77030, United States
  • CHU d'Amiens
    Amiens, France
  • Hôpital Avicenne
    Bobigny, France
  • CHU de Brest
    Brest, France
  • CHU de Caen
    Caen, France
  • CHU Clermont Ferrand
    Clermont Ferrand, 63000, France
  • Hôpital Claude Huriez
    Lille, France
  • CHU Dupuytren
    Limoges, France
  • Hôpital Ambroise Paré
    Marseille, France
  • Hôpital Nord
    Marseille, France
  • Hôpital Central
    Nancy, France
  • CHU Hôtel Dieu
    Nantes, France
  • Hôpital l'Archet II
    Nice, France
  • Hôpital Necker
    Paris, France
  • Hôpital Tenon
    Paris, France
  • CHU Lyon Sud
    Pierre Bénite, 69495, France
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, France
  • CHU Milétrie
    Poitiers, France
  • CHU Hôpital Sud
    Rennes, France
  • CHU de Saint-Etienne
    Saint-Etienne, France
  • Hôpital Purpan
    Toulouse, France
  • Hôpital Bretonneau
    Tours, France
  • Hôpital des Hauts Clos
    Troyes, France
08

References and documents

Publications

  • Arock M. A new therapeutic advance for symptomatic systemic mastocytosis? Lancet. 2017 Feb 11;389(10069):576-578. doi: 10.1016/S0140-6736(16)31655-5. Epub 2017 Jan 7. No abstract available. PubMed 28069280 ↗
  • Lortholary O, Chandesris MO, Bulai Livideanu C, Paul C, Guillet G, Jassem E, Niedoszytko M, Barete S, Verstovsek S, Grattan C, Damaj G, Canioni D, Fraitag S, Lhermitte L, Georgin Lavialle S, Frenzel L, Afrin LB, Hanssens K, Agopian J, Gaillard R, Kinet JP, Auclair C, Mansfield C, Moussy A, Dubreuil P, Hermine O. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet. 2017 Feb 11;389(10069):612-620. doi: 10.1016/S0140-6736(16)31403-9. Epub 2017 Jan 7. PubMed 28069279 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2008
First posted
Dec 23, 2008
Start
Dec 2008
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Results delay requested
Dec 12, 2018
Last update
Dec 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00814073
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Dec 23, 2008
Start date
Dec 2008
Primary completion
Nov 2015
Completion
Nov 2015
Last update
Dec 3, 2019

Study contacts

Olivier Lortholary, MD, PhD
principal investigator · Hôpital Necker, Paris, France

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion